Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival

Leukemia & lymphoma/Leukemia and lymphoma 2026 Open access

Read full text
Authors: Andrew Kuykendall, Francesca Palandri, Mirko Fillbrunn, Tom Liu, Shiyuan Zhang, Adina Zhang, Ryan Simpson, Gautam Sajeev, James Signorovitch, Dwaipayan Patnaik, Aaron T. Gerds
DOI: 10.1080/10428194.2026.2628361
Cited by: 2
References: 29

Abstract

Characterization of real-world outcomes in ruxolitinib-treated patients with myelofibrosis and anemia is limited. This retrospective analysis of the US Flatiron Health electronic health record–derived deidentified database focused on patients with myelofibrosis who did or did not have anemia and received ruxolitinib. More baseline anemic vs nonanemic patients received

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Multiple Myeloma Research and Treatments Platelet Disorders and Treatments

Publication details

Journal / source
Leukemia & lymphoma/Leukemia and lymphoma
Publisher
Informa UK Limited
Volume
67
Issue
5
Pages
1088–1099
Publication date
27 February 2026
Language
EN